Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Антиангинальная терапия: фокус на ранолазин
Антиангинальная терапия: фокус на ранолазин
Карпов Ю.А. Антиангинальная терапия: фокус на ранолазин. Consilium Medicum. 2013; 15 (5): 26–31.
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. ВНОК. Диагностика и лечение стабильной стенокардии. Российские рекомендации (второй пересмотр). Кардиоваскулярная терапия и профилактика (Прил. 4). 2008.
2. The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Guidelines on the management of stable angina pectoris: executive summary. Eur Heart J 2006; 27: 1341–81.
3. Карпов Ю.А., Сорокин Е.В. Стабильная ИБС: стратегия и тактика лечения. 3-е изд. М.: МИА, 2012.
4. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients with Stable Ischemic Heart Disease. Circulation 2012; 126: e354–e471.
5. Aslam S, Gray D. Ranolazine (Ranexa) in the treatment of chronic stable angina. Adv Ther 2010; 27 (4): 193–201.
6. Letienne R, Vie B, Puech A et al. Evidence that ranolazine behaves as a weak beta1- and beta2-adrenoceptor antagonist in the cat cardiovascular system. Naunyn Schmiedebergs. Arch Pharmacol 2001; 363 (4): 464–71.
7. Allely MC, Brown CM, Kenny BA et al. Modulation of alpha 1-adrenoceptors in rat left ventricle by ischaemia and acyl carnitines: Protection by ranolazine. J Cardiovasc Pharmacol 1993; 21 (6): 869–73.
8. Zhao G, Walsh E, Shryock JC et al. Antiadrenergic and hemodynamic effects of ranolazine in conscious dogs. J Cardiovasc Pharmacol 2011; 57 (6): 639–47.
9. Chaitman BR, Skettino SL, Parker JO et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol 2004; 43 (8): 1375–82.
10. Estacion M, Waxman SG, Dib-Hajj SD. Effects of ranolazine on wild-type and mutant hNav1.7 channels and on DRG neuron excitability. Mol Pain 2010; 6: 35.
11. Melloni C, Newby LK. Metabolic efficiency with ranolazine for less ischemia in non-ST elevation acute coronary syndromes (MERLIN TIMI-36) study. Expert Rev Cardiovasc Ther 2008; 6 (1): 9–16.
12. Dobesh PP, Trujillo TC. Ranolazine: A new option in the management of chronic stable angina. Pharmacotherapy 2007; 27 (12): 1659–76.
13. Siddiqui MA, Keam SJ. Ranolazine: A review of its use in chronic stable angina pectoris. Drugs 2006; 66 (5): 693–710.
14. Chaitman BR, Pepine CJ, Parker JO et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: A randomized controlled trial. JAMA 2004; 291 (3): 309–16.
15. US Food and Drug Administration. Available from: http://www.fda. gov/ohrms/dockets/ac/03/briefing/4012B2_01_Action%20Letter.pdf. Accessed April 4, 2007.
16. Stone PH, Gratsiansky NA, Blokhin A et al. Antianginal efficacy of ranolazine when added to treatment with amlodipine: The ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol 2006; 48 (3): 566–75.
17. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E et al. Evaluation of a novel anti-ischemic agent in acute coronary syndromes: Design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-elevation acute coronary syndromes (MERLIN)-TIMI 36 trial. Am Heart J 2006; 151 (6): e1181–e1189.
18. Arnold SV, Morrow DA, Lei Y et al. Economic impact of angina after an acute coronary syndrome: Insights from the MERLIN-TIMI 36 trial. Circ Cardiovasc Qual Outcomes 2009; 2 (4): 344–53.
19. Arnold SV, Morrow DA, Wang K et al. Effects of ranolazine on disease-specific health status and quality of life among patients with acute coronary syndromes: Results from the MERLIN-TIMI 36 randomized trial. Circ Cardiovasc Qual Outcomes 2008; 1 (2): 107–15.
2. The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Guidelines on the management of stable angina pectoris: executive summary. Eur Heart J 2006; 27: 1341–81.
3. Карпов Ю.А., Сорокин Е.В. Стабильная ИБС: стратегия и тактика лечения. 3-е изд. М.: МИА, 2012.
4. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients with Stable Ischemic Heart Disease. Circulation 2012; 126: e354–e471.
5. Aslam S, Gray D. Ranolazine (Ranexa) in the treatment of chronic stable angina. Adv Ther 2010; 27 (4): 193–201.
6. Letienne R, Vie B, Puech A et al. Evidence that ranolazine behaves as a weak beta1- and beta2-adrenoceptor antagonist in the cat cardiovascular system. Naunyn Schmiedebergs. Arch Pharmacol 2001; 363 (4): 464–71.
7. Allely MC, Brown CM, Kenny BA et al. Modulation of alpha 1-adrenoceptors in rat left ventricle by ischaemia and acyl carnitines: Protection by ranolazine. J Cardiovasc Pharmacol 1993; 21 (6): 869–73.
8. Zhao G, Walsh E, Shryock JC et al. Antiadrenergic and hemodynamic effects of ranolazine in conscious dogs. J Cardiovasc Pharmacol 2011; 57 (6): 639–47.
9. Chaitman BR, Skettino SL, Parker JO et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol 2004; 43 (8): 1375–82.
10. Estacion M, Waxman SG, Dib-Hajj SD. Effects of ranolazine on wild-type and mutant hNav1.7 channels and on DRG neuron excitability. Mol Pain 2010; 6: 35.
11. Melloni C, Newby LK. Metabolic efficiency with ranolazine for less ischemia in non-ST elevation acute coronary syndromes (MERLIN TIMI-36) study. Expert Rev Cardiovasc Ther 2008; 6 (1): 9–16.
12. Dobesh PP, Trujillo TC. Ranolazine: A new option in the management of chronic stable angina. Pharmacotherapy 2007; 27 (12): 1659–76.
13. Siddiqui MA, Keam SJ. Ranolazine: A review of its use in chronic stable angina pectoris. Drugs 2006; 66 (5): 693–710.
14. Chaitman BR, Pepine CJ, Parker JO et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: A randomized controlled trial. JAMA 2004; 291 (3): 309–16.
15. US Food and Drug Administration. Available from: http://www.fda. gov/ohrms/dockets/ac/03/briefing/4012B2_01_Action%20Letter.pdf. Accessed April 4, 2007.
16. Stone PH, Gratsiansky NA, Blokhin A et al. Antianginal efficacy of ranolazine when added to treatment with amlodipine: The ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol 2006; 48 (3): 566–75.
17. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E et al. Evaluation of a novel anti-ischemic agent in acute coronary syndromes: Design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-elevation acute coronary syndromes (MERLIN)-TIMI 36 trial. Am Heart J 2006; 151 (6): e1181–e1189.
18. Arnold SV, Morrow DA, Lei Y et al. Economic impact of angina after an acute coronary syndrome: Insights from the MERLIN-TIMI 36 trial. Circ Cardiovasc Qual Outcomes 2009; 2 (4): 344–53.
19. Arnold SV, Morrow DA, Wang K et al. Effects of ranolazine on disease-specific health status and quality of life among patients with acute coronary syndromes: Results from the MERLIN-TIMI 36 randomized trial. Circ Cardiovasc Qual Outcomes 2008; 1 (2): 107–15.
Авторы
Ю.А.Карпов
Институт клинической кардиологии им.А.Л.Мясникова ФГБУ РКНПК Минздрава РФ
Институт клинической кардиологии им.А.Л.Мясникова ФГБУ РКНПК Минздрава РФ
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.